300. IgG4関連疾患 IgG4-related disease Clinical trials / Disease details

臨床試験数 : 40 / 薬物数 : 47 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 10 of 40 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05746689 (ClinicalTrials.gov)	March 1, 2023	13/2/2023	Study of Sirolimus in IgG4-related Disease	Combination Therapy of Sirolimus and Glucocorticoids for the Maintenance of Remission in Patients Wi ...	IgG4-related Disease	Drug: Sirolimus	Peking University International Hospital	NULL	Not yet recruiting	18 Years	80 Years	All	20	N/A	NULL
2	NCT05728684 (ClinicalTrials.gov)	February 28, 2023	17/1/2023	Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease	A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombina ...	IgG4 Related Disease	Biological: CM310	Beijing Friendship Hospital	NULL	Not yet recruiting	18 Years	N/A	All	20	N/A	NULL
3	NCT05625581 (ClinicalTrials.gov)	November 10, 2022	10/11/2022	Tofatib Treatment for IgG4-related Disease	Clinical Study on the Efficacy and Safety of Tofatib and Cyclophosphamide in the Treatment of Active ...	IgG4-related Disease	Drug: tofacitinib	Changhai Hospital	NULL	Recruiting	18 Years	75 Years	All	40		China
4	NCT05662241 (ClinicalTrials.gov)	September 30, 2022	14/12/2022	A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy ...	IgG4 Related Disease	Drug: Obexelimab;Other: Placebo	Zenas BioPharma (USA), LLC	NULL	Recruiting	18 Years	N/A	All	200	Phase 3	United States
5	ChiCTR2200062904	2022-08-23	2022-08-23	A multicenter, randomized, open-label clinical study on the efficacy and safety of iguratimod in the ...	A multicenter, randomized, open-label clinical study on the efficacy and safety of iguratimod in the ...	IgG4-related disease	glucocorticoid monotherapy group:glucocorticoid monotherapy;glucocorticoid combined with iguratimodg ...	Beijing Friendship Hospital Affiliated to Capital Medical University	NULL	Recruiting	18	100	Both	glucocorticoid monotherapy group:122;glucocorticoid combined with iguratimod group:122;	Phase 4	China
6	NCT04602598 (ClinicalTrials.gov)	August 1, 2022	20/10/2020	Zanubrutinib in Patients With IgG4-Related Disease	A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease	IgG4 Related Disease	Drug: Zanubrutinib 80 MG	Matthew C. Baker	Stanford University	Recruiting	18 Years	85 Years	All	10	Phase 2	United States
7	JPRN-jRCTs051210171	07/02/2022	07/02/2022	The treatment using indigo naturalis for autoimmune pancreatitis	Safety of indigo naturalis in patients with autoimmune pancreatitis- Indigo naturalis for autoimmune ...	Autoimmune pancreatitis Autoimmune pancreatitis	Administration of indigo naturalis	Kamata Ken	NULL	Recruiting	>= 20age old	Not applicable	Both	10	Phase 2	Japan
8	JPRN-jRCT2071210001	18/08/2021	01/04/2021	A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease	A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	IgG4-Related Disease	RCP: Blinded treatment on Day 1, Day 15, and Week 26: - Inebilizumabgroup: Inebilizumab300 mg intrave ...	Katayama Sota	NULL	Recruiting	>= 20age old	Not applicable	Both	16	Phase 3	USA;China;Australia;Canada;France;Italy;Germay;Hong Kong;Hungary;Israel;Ireland;Mexico;Netherlands;P ...
9	EUCTR2020-000417-33-SE (EUCTR)	30/03/2021	19/11/2020	Inebilizumab efficacy and safety in IgG4 related disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United States;Hong Kong;Spain;Ukraine;Ireland;Turkey;Israel;United Kingdom;Italy;India;France;Hungar ...
10	EUCTR2020-000417-33-NL (EUCTR)	26/02/2021	29/09/2020	Inebilizumab efficacy and safety in IgG4 related disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United States;Hong Kong;Spain;Ukraine;Ireland;Turkey;Israel;United Kingdom;Italy;India;France;Hungar ...

First Previous1 2 3 4Next Last